美罗培南-法硼巴坦：抵抗革兰氏阴性菌感染的新武器。
Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
机构信息
Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI 48109, USA.
Department of Pharmacy Services, Sinai-Grace Hospital, Detroit, MI 482351, USA.
出版信息
Future Microbiol. 2018 Jul;13(9):971-983. doi: 10.2217/fmb-2018-0054. Epub 2018 Apr 25.
Abstract
Meropenem-vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE). The efficacy of meropenem-vaborbactam for the treatment of complicated urinary tract infections and acute pyelonephritis was demonstrated in a Phase III trial (TANGO I). Preliminary data from TANGO II, a separate Phase III study, support the efficacy of meropenem-vaborbactam for the treatment of infections caused by CRE. Overall, meropenem-vaborbactam appears to be safe and well tolerated. It has favorable toxicity, pharmacokinetic and pharmacodynamic profiles compared with other antibiotics with activity against CRE. Meropenem-vaborbactam is an important addition to the current armamentarium of antimicrobial agents with activity against K. pneumoniae carbapenemase-producing CRE.
摘要
美罗培南-法硼巴坦是一种碳青霉烯类药物和一种环状硼酸β-内酰胺酶抑制剂的固定剂量组合产品，对产碳青霉烯酶的碳青霉烯类耐药肠杆菌科（CRE）具有强大的体外活性。美罗培南-法硼巴坦治疗复杂性尿路感染和急性肾盂肾炎的疗效在 III 期临床试验（TANGO I）中得到了证实。来自单独的 III 期研究 TANGO II 的初步数据支持美罗培南-法硼巴坦治疗 CRE 引起的感染的疗效。总的来说，美罗培南-法硼巴坦似乎安全且耐受良好。与其他具有抗 CRE 活性的抗生素相比，它具有良好的毒性、药代动力学和药效学特征。美罗培南-法硼巴坦是对抗产碳青霉烯酶肺炎克雷伯菌的现有抗菌药物武器库的重要补充。
相似文献
1
Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.美罗培南-法硼巴坦：抵抗革兰氏阴性菌感染的新武器。
Future Microbiol. 2018 Jul;13(9):971-983. doi: 10.2217/fmb-2018-0054. Epub 2018 Apr 25.
2
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.亚胺培南-西司他丁钠和美罗培南-法硼巴坦：两种新型碳青霉烯-β-内酰胺酶抑制剂复方制剂。
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
3
Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.美罗培南/威巴利汀：治疗复杂性尿路感染的综述。
Drugs. 2018 Aug;78(12):1259-1270. doi: 10.1007/s40265-018-0966-7.
4
Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.沃博巴坦（一种新型β-内酰胺酶抑制剂）与美罗培南联合的药代动力学/药效学研究。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01659-18. Print 2019 Jan.
5
Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.美罗培南-法硼巴坦对产 KPC 碳青霉烯酶耐药肠杆菌科细菌感染小鼠模型的作用。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01446-17. Print 2018 Jan.
6
Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.美罗培南-法硼巴坦对肾盂肾炎小鼠模型中碳青霉烯类耐药肠杆菌科的活性。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01439-17. Print 2018 Jan.
7
Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.美罗培南-法硼巴坦治疗成人复杂性尿路感染和其他侵袭性感染。
Expert Rev Anti Infect Ther. 2018 Dec;16(12):865-876. doi: 10.1080/14787210.2018.1542300. Epub 2018 Nov 5.
8
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.美罗培南和瓦博巴坦：加强对抗碳青霉烯类耐药肠杆菌科细菌的战斗。
Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28.
9
Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.美罗培南-法硼巴坦：一种碳青霉烯类和β-内酰胺酶抑制剂，对碳青霉烯类耐药的肠杆菌科具有活性。
Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1411-1419. doi: 10.1007/s10096-018-3260-4. Epub 2018 Apr 19.
10
An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.美罗培南-巴坦的药代动力学和药效学特性评估
Infect Dis Ther. 2020 Dec;9(4):769-784. doi: 10.1007/s40121-020-00344-z. Epub 2020 Oct 6.
引用本文的文献
1
Strategic re-engineering of antibiotics.抗生素的战略重组
Nat Rev Bioeng. 2025 Mar;3(3):213-229. doi: 10.1038/s44222-024-00250-w. Epub 2024 Oct 15.
2
Difficult-to-Treat Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal.重症患者难治性感染：综述与治疗建议
Antibiotics (Basel). 2025 Feb 11;14(2):178. doi: 10.3390/antibiotics14020178.
3
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.攻克外膜：促进化合物进入革兰氏阴性菌病原体。
NPJ Antimicrob Resist. 2023 Dec 20;1(1):17. doi: 10.1038/s44259-023-00016-1.
4
A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections.2016 年至 2023 年批准用于治疗复杂性尿路感染的新药疗效和安全性的系统评价。
Ann Med. 2024 Dec;56(1):2403724. doi: 10.1080/07853890.2024.2403724. Epub 2024 Nov 12.
5
Meropenem/Vaborbactam-A Mechanistic Review for Insight into Future Development of Combinational Therapies.美罗培南/瓦博巴坦——深入了解联合疗法未来发展的机制性综述
Antibiotics (Basel). 2024 May 21;13(6):472. doi: 10.3390/antibiotics13060472.
6
Change in Diagnosis of Infection in the Treatment-Failure Era.治疗失败时代感染诊断的变化
Antibiotics (Basel). 2024 Apr 12;13(4):357. doi: 10.3390/antibiotics13040357.
7
Boronic acid inhibitors of penicillin-binding protein 1b: serine and lysine labelling agents.青霉素结合蛋白 1b 的硼酸抑制剂：丝氨酸和赖氨酸标记试剂。
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2305833. doi: 10.1080/14756366.2024.2305833. Epub 2024 Feb 27.
8
New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties.新型抗多重耐药革兰氏阴性菌抗生素在肝移植中的临床应用、毒性和药代动力学/药效学特性。
Transpl Int. 2024 Feb 1;37:11692. doi: 10.3389/ti.2024.11692. eCollection 2024.
9
Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.用于治疗儿童多重耐药革兰氏阴性菌感染的新型β-内酰胺类抗生素：一项叙述性综述
Microorganisms. 2023 Jul 13;11(7):1798. doi: 10.3390/microorganisms11071798.
10
Chemical Basis of Combination Therapy to Combat Antibiotic Resistance.联合治疗对抗抗生素耐药性的化学基础。
JACS Au. 2023 Jan 31;3(2):276-292. doi: 10.1021/jacsau.2c00532. eCollection 2023 Feb 27.
本文引用的文献
1
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.美罗培南-维巴坦与哌拉西林-他唑巴坦治疗复杂性尿路感染的临床疗效和微生物清除率：TANGO I 随机临床试验。
JAMA. 2018 Feb 27;319(8):788-799. doi: 10.1001/jama.2018.0438.
2
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.单剂量药代动力学和安全性研究：美罗培南-维巴坦在慢性肾功能损害患者中的应用。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02103-17. Print 2018 Mar.
3
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
4
Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an Hollow-Fiber Model.模拟美罗培南和沃博巴坦人体剂量方案对中空纤维模型中耐碳青霉烯类肠杆菌科的活性。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01969-17. Print 2018 Feb.
5
Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.美罗培南-法硼巴坦对产 KPC 阳性肠杆菌科临床分离株的活性。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01904-17. Print 2018 Jan.
6
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.产 KPC 肺炎克雷伯菌中美罗培南-沃博巴坦耐药选择、耐药预防及突变体的分子机制
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01694-17. Print 2017 Dec.
7
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
8
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.沃博巴坦：β-内酰胺酶抑制谱及耐药机制对肠杆菌科活性的影响。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01443-17. Print 2017 Nov.
9
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.美罗培南-法硼巴坦对 2014 年期间全球收集的当代革兰氏阴性分离株进行了测试，包括耐碳青霉烯类、产 KPC、多药耐药和广泛耐药的肠杆菌科。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00567-17. Print 2017 Sep.
10
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.头孢他啶-阿维巴坦在治疗耐碳青霉烯类肺炎克雷伯菌血症方面优于其他治疗方案。
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00883-17. Print 2017 Aug.
Zotero 插件